Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Inventory (2017 - 2025)

Organogenesis Holdings has reported Inventory over the past 9 years, most recently at $29.6 million for Q4 2025.

  • Quarterly results put Inventory at $29.6 million for Q4 2025, up 13.0% from a year ago — trailing twelve months through Dec 2025 was $29.6 million (up 13.0% YoY), and the annual figure for FY2025 was $29.6 million, up 13.0%.
  • Inventory for Q4 2025 was $29.6 million at Organogenesis Holdings, down from $39.6 million in the prior quarter.
  • Over the last five years, Inventory for ORGO hit a ceiling of $39.6 million in Q3 2025 and a floor of $22.7 million in Q1 2022.
  • Median Inventory over the past 5 years was $27.4 million (2024), compared with a mean of $27.7 million.
  • Biggest five-year swings in Inventory: dropped 23.5% in 2022 and later soared 46.41% in 2025.
  • Organogenesis Holdings' Inventory stood at $25.0 million in 2021, then decreased by 0.96% to $24.8 million in 2022, then grew by 14.0% to $28.3 million in 2023, then decreased by 7.2% to $26.2 million in 2024, then rose by 13.0% to $29.6 million in 2025.
  • The last three reported values for Inventory were $29.6 million (Q4 2025), $39.6 million (Q3 2025), and $33.0 million (Q2 2025) per Business Quant data.